EPCAM and hepatocellular carcinoma: We have also demonstrated that enforce expression of EpICD in these EpCAM-null HCC cells could enhance cell proliferation (Figure 5B) and resistance against the standard of care drug for HCC, sorafenib (Figure 5C).